


Mitigating Strategies Against Emerging and Re-Emerging Bacterial Infections

Lead Guest Editor: Amjad Islam Aqib

Guest Editors: Kun Li and Muhammad Ijaz





Mitigating Strategies Against Emerging and Re-Emerging Bacterial Infections

BioMed Research International

Mitigating Strategies Against Emerging and Re-Emerging Bacterial Infections

Lead Guest Editor: Amjad Islam Aqib

Guest Editors: Kun Li and Muhammad Ijaz



Copyright © 2023 Hindawi Limited. All rights reserved.

This is a special issue published in “BioMed Research International.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Section Editors

Penny A. Asbell, USA
David Bernardo , Spain
Gerald Brandacher, USA
Kim Bridle , Australia
Laura Chronopoulou , Italy
Gerald A. Colvin , USA
Aaron S. Dumont, USA
Pierfrancesco Franco , Italy
Raj P. Kandpal , USA
Fabrizio Montecucco , Italy
Mangesh S. Pednekar , India
Letterio S. Politi , USA
Jinsong Ren , China
William B. Rodgers, USA
Harry W. Schroeder , USA
Andrea Scribante , Italy
Germán Vicente-Rodriguez , Spain
Momiao Xiong , USA
Hui Zhang , China

Academic Editors

Allergy

Luisa Brussino , Italy
Denis Caillaud , France
Cristiano Caruso , Italy
Paolo Colombo , Italy
Enrico Compalati , Italy
Erika Di Zazzo , Italy
Dong Fang, China
Rodrigo S Ferreira , Brazil
Enrico Heffler , Italy
Stanislav Ignatov , Russia
Robert Movérare , Sweden
Mamadou Ousmane Ndiath , Madagascar
Dejan Radovanovic , Italy
Frederico S. Regateiro , Portugal
Taiyoun Rhim , Republic of Korea

Contents

Development of a Novel Vaccine Candidates against *Cardiobacterium valvarum* through Reverse Vaccinology and Computational Approaches

Faisal F. Albaqami , Ali Altharawi , Hassan N. Althurwi, Khalid M. Alharthy, Muhammad Tahir ul Qamar , Ziyad Tariq Muhseen, and Madiha Iqbal 

Research Article (16 pages), Article ID 6325568, Volume 2023 (2023)

Research Article

Development of a Novel Vaccine Candidates against *Cardiobacterium valvarum* through Reverse Vaccinology and Computational Approaches

Faisal F. Albaqami ¹, Ali Altharawi ², Hassan N. Althurwi,¹ Khalid M. Alharthy,¹ Muhammad Tahir ul Qamar ³, Ziyad Tariq Muhseen,⁴ and Madiha Iqbal ⁵

¹Department of Pharmacology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia

²Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia

³Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Faisalabad 38000, Pakistan

⁴Department of Pharmacy, Al-Mustaqbal University College, Hillah, Babylon 51001, Iraq

⁵Department of Health and Biological Sciences, Abasyn University, Peshawar, Pakistan

Correspondence should be addressed to Faisal F. Albaqami; f.albaqami@psau.edu.sa and Madiha Iqbal; madiha_iqbal8630@yahoo.com

Received 17 December 2022; Revised 10 March 2023; Accepted 5 May 2023; Published 28 June 2023

Academic Editor: Amjad Islam Aqib

Copyright © 2023 Faisal F. Albaqami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Antibiotic resistance is a major public health concern that has resulted in high healthcare costs, increased mortality, and the emergence of novel bacterial diseases. *Cardiobacterium valvarum*, an antibiotic-resistant bacterium, is one of the leading causes of heart disease. Currently, there is no licensed vaccination against *C. valvarum*. In this research, an *in silico*-based vaccine was designed against *C. valvarum* using reverse vaccinology, bioinformatics, and immunoinformatics techniques. 4206 core proteins, 2027 nonredundant proteins, and 2179 redundant proteins were predicted. Among nonredundant proteins, 23 proteins were predicted in an extracellular membrane, 30 in the outer membrane, and 62 in the periplasmic membrane region. After applying several subtractive proteomics filters, two proteins, TonB-dependent siderophore receptor and hypothetical protein, were chosen for epitope prediction. In the epitope selection phase, B and T-cellepitopes were analyzed and shortlisted for vaccine design. The vaccine model was designed by linking selected epitopes with GPGPG linkers to avoid flexibility. Furthermore, the vaccine model was linked to cholera toxin B adjuvant to induce a proper immune response. The docking approach was utilized to analyze binding affinity to immune cell receptors. Molecular docking results predicted 12.75 kcal/mol for a Vaccine with MHC-I, 6.89 for a vaccine with MHC-II, and 19.51 vaccine with TLR-4. The MMGBSA estimated -94, -78, and -76 kcal/mol for TLR-4 and vaccine, MHC-I and vaccine, and MHC-II and vaccine, while the MMPBSA analysis estimated -97, -61, and -72 kcal/mol for TLR-4 with the vaccine, MHC-I with vaccine, and MHC-II with a vaccine. Molecular dynamic simulation analysis revealed that the designed vaccine construct has proper stability with immune cell receptors as it is essential for inducing an immune response. In conclusion, we observed that the model vaccine candidate has the potency to induce an immune response in the host. However, the study is designed purely on a computational basis; hence, experimental validation is strongly recommended.

1. Introduction

Bacterial infections are usually treated with antibiotics/medicines. Long-term usage of these medicines leads to antibiotic resistance [1]. Resistant bacteria become difficult to

treat when compared to nonresistant bacteria, both in the case of animal or human infections. The consequences of antibiotic resistance include prolonged hospitalization, an increase in medical cost, and an increased mortality rate [2]. The prescription of medicines and usage of antibiotics

needs to carry on with great care. Antibiotic resistance is a major threat if these practices are not changed [3]. Behavior modifications will require a change in lifestyles by requiring vaccinations, hand washing, safe sexual activity, and a good self-hygiene regime; infection sickness that affects the heart or blood vessels is referred to as a cardiovascular disease [4].

The elevated risk of blood clots and fat deposits in the arteries (atherosclerosis) is usually associated with cardiovascular disease. It is linked with arterial damage in different organs as well, for example, kidneys, brain, eyes, and heart [5]. Cardiovascular disease is one of the primary causes of death and disability in the United Kingdom, yet it may often be avoided by following a healthy lifestyle. Endocarditis is caused by *Cardiobacterium valvarum*, a recently discovered "*Haemophilus* species, *Aggregatibacter actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella kingae*" commonly known as (HACEK) pathogen. In terms of culture, gram stain, and growth properties, these two species of *Cardiobacterium* are morphologically indistinguishable [6]. Under standard CO₂ incubation conditions, isolates of *C. valvarum* on 5 percent sheep blood show optimal growth by day 3, but with limited growth on chocolate agar and sheep blood agar, colonies are nonhemolytic to mildly α-hemolytic. Using 16S PCR, the *Cardiobacterium* species can be differentiated [7]. *Cardiobacterium* is a fastidious gram-negative bacillus that is an infrequent human pathogen in therapeutic circumstances. *C. valvarum* and *C. hominis* are the two species of the genus *Cardiobacterium*, with the latter having a higher rate of infection. Due to its phenotypic characteristics, the clinical features of *C. valvarum* infection have not yet been thoroughly researched [7]. Since it can be challenging to identify *C. valvarum*, referral labs that use molecular identification techniques may be needed. The clinical features of *C. valvarum* endocarditis were evaluated in one of the case studies, which involved a 36-year-old man who had suffered an abrupt myocardial infarction and was found to have bicuspid aortic valve subacute bacterial endocarditis [8]. Vaccine discovery is a significant breakthrough that represents a more rational way to dealing with biomedical sciences [9]. Vaccines developed using conventional vaccinology have several disadvantages as compared to epitope-based chimeric vaccines. For example, they can replace many wet lab studies and save time because they are less expensive to manufacture and do not require microbial cultivation [10]. In this work, reverse vaccinology, immunoinformatics, and different biophysical approaches were utilized for vaccine target identification, epitope prediction, and prioritization and designing of multi-epitope vaccine against the target pathogen. They are a safer alternative since they are highly specific and stable and do not contain full viruses [11]. Therefore, the approach used in computer-aided vaccine designs is a better reciprocal choice that will expedite, shorten, and increase efficacy [12]. The study is mainly aimed at designing of multi-epitope vaccine construct against *C. valvarum* by using several immunoinformatics and reverse vaccinology approaches.

2. Research Methodology

The following are the main steps used in the methodology to design the multi-epitope vaccine against *C. valvarum* as shown in the flow chart mentioned in Figure 1.

2.1. Proteome Retrieval of *C. valvarum* and Subtraction of Core Proteins. In this step, the whole complete proteome of *C. valvarum* was retrieved from the "National Center for Biotechnology Information" database (NCBI) (<https://www.ncbi.nlm.nih.gov/>) and converted into FASTA format [13]. Core sequences were predicted through Bacterial Pan-Genome Analysis (BPGA) (<https://iicb.res.in/bpga/>) [14]. Core protein was subjected to subtractive bioinformatics analysis to find a good vaccine candidate. These are computational-based approaches to select vaccine targets by excluding the nonessential proteins from the vaccine construct. In the first step, the paralogous proteins were removed (that were added in CD/hit analysis) (<https://sites.google.com/view/cd-hit>) [15]. The nonsimilar proteins were considered for surface localization which was checked by PSORTb (<https://www.psort.org/psortb/server>) [16], and virulent protein sequence was analyzed in Virulence Factor Database (VFDB) (<https://www.psort.org/psortb/analysis>) [17]. In addition, using TMHMM 2.0 tool (<https://services.healthtech.dtu.dk/services/TMHMM-2.0/>) predicts the transmembrane helices with greater than 1 cut-off value [18]. Vaxijen 2.0 (<http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html>) online web server was used for the analysis of antigenicity with a threshold value of 0.5 [19]. Furthermore, to check the allergenicity of the protein, Allertop 2.0 was used [20]. Next, physicochemical properties were analyzed by the protparam tool (<https://web.expasy.org/cgi-bin/protparam/protparam>) [21]. Next, to check the analysis against human (taxid: 9606) and 3 *Lactobacillus* species: "*L. rhamnosus* (taxid: 47715), *L. johnsonii* (taxid: 33959), and *L. casei* (taxid: 1582)," homology analysis was done through BLASTp (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) [22]. The shortlisted proteins were further subjected to epitope prediction.

2.2. Epitope Prediction Phase. In this phase, B-cell epitopes and T-cell epitopes were predicted from the target proteins using the immune epitope database and analysis resource IEDB tool (<https://www.iedb.org/>) [23]. This prediction is pivotal to obtain a humoral and cellular response against the antigen. BepiPred 2.0 [24] was utilized to predict the B-cell linear epitopes. Furthermore, the predicted B-cell epitopes were utilized to predict the T-cell epitope, and this procedure was completed successfully using the IEDB T-cell prediction tool, with epitopes prioritized based on low percentile score. In addition, the predicted epitopes having binding potency with the DRB × 0101 allele were analyzed using MHCpred tool [25]. Vaxijen 2.0, ToxinPred, InvivoGen, and Allertop 2.0 tools (<https://www.ddg-pharmfac.net/AllerTOP/>) were used to check their antigenicity, toxicity, allergenicity, and solubility [26], respectively. The short-listed epitopes will then be used to design a vaccine.

2.3. Vaccine Construction Phase. To overcome the issue of a single peptide vaccine, the multi-epitope vaccine was constructed, which consists not only of a single epitope but many different types of immune-dominant epitopes [27]. To evoke substantial immune responses, multi-peptide vaccine construct was designed [28]. To create a multi-epitope vaccine construct, GPGPG linkers were used to link the




FIGURE 1: Schematic representation of research methodology.

selected epitopes. Finally, the vaccine construct was linked to a good and safe adjuvant (Cholera Toxin-B Subunit) [29].

2.4. Physicochemical Properties of the Multi-epitope Vaccine Construct. In this step, the multi-epitope vaccine construct was checked for physicochemical properties through the online ProtParam tool (ExPasy) web server [30]. The following properties of the designed vaccine were checked: molecular weight (MW); instability index (II); and aliphatic index (AI) [31].

2.5. Vaccine's Structure Modeling. The structure was predicted through the 3DPro tool using the sequence of vaccine construct [32]. For molecular recognition, the prediction of the stable vaccine structure is essential. An online Galaxy

web server and Galaxy Refine 2 tool were used for loop modeling [33] and refinement, respectively, [34].

2.6. In Silico Cloning and Disulfide Engineering. Disulfide engineering was done by Design 2.0 webserver [35]. In this step, the vaccine candidate's structural stability was improved and the mutant structure was created by making disulfide bonds. In the *E. coli* system expression of the cloned vaccine sequence, codon optimization approach was used. In this approach, the multi-epitope vaccine sequence is reversed to the DNA sequence using Java Codon Adaptation Tool (JCat) [36].

2.7. Molecular Docking and Refinement. The PATCHDOCK [37] and FIREDOCK [38] web servers were used to perform the molecular docking and refinement of docking results.

Docking of the vaccine with “MHC-I, MHC-II, and TLR-4” receptors of the immune cells was performed [39]. The docked solutions of PATCHDOCK were submitted for refinement. Numerous steric clash errors of intermolecular conformational are removed using the FIREDOCK server from the solutions and reranked them [31].

2.8. Molecular Dynamic Simulation. The molecular dynamic simulation was applied for the assessment of the movement of docked molecules. In the molecular dynamic simulation, the complex was evaluated for 100 ns of time period using AMBER [40]. As a force field, FF14SB was used [41]. On the other hand, for the vaccine-receptor complex, the submersion “TIP3P3 water box (12 Angstrom)” was used [27]. Moreover, the SHAKE algorithm was used to constrain a hydrogen bond. Furthermore, these complexes were equilibrated and heated, and, afterwards, a production run was carried out for 100 ns [42].

2.9. Calculations for Binding-Free Energies. Binding-free energies of docked complexes were estimated through “MM/PBSA and MM/GBSA” available in AMBER20 [43]. With the help of the MMPBSA.py module of AMBER, both analyses were conducted. A total of 100 frames were considered for the calculation of the binding free energies [44].

2.10. C-Immune Simulations. The final vaccine constructs immunogenic efficacy was evaluated with the help of *in silico* immune simulation, by using “C-immSim server 10.1 [45]”. The vaccine’s potential to interact with the immune system can be predicted in this method (<http://tools.iedb.org/population/>).

3. Results

3.1. Complete Genome Extraction and Subtractive Proteomics Analysis. Two fully sequenced genomes of *C. valvarum* bacterium were retrieved from NCBI. BPGA analysis revealed that the fully sequenced genome consisted of 4206 core sequences. The core sequence was further considered for the selection of good vaccine targets. CD-HIT analysis predicted 2027 nonredundant proteins. The nonredundant proteins were processed for subcellular localization analysis. In subcellular localization analysis, 115 proteins were predicted in subcellular localized regions. Among total subcellular localized proteins, 23 were extracellular, 30 proteins were predicted in the outer-membrane region, and 62 proteins were predicted in the periplasmic membrane region. Nineteen subcellular localized proteins were expected to be antigenic, 9 antigenic proteins were predicted to be allergenic, and 2 of the remaining 10 proteins were predicted to be unstable having >100MW. Among the 8 filtered proteins, 3 proteins were similar to humans, and 3 proteins were homologs to normal flora. Overall categories and numbers of subtracted proteins are presented in Figure 2.

3.2. Epitope Mapping Phase. After applying several subtractive filters, only two proteins TonB-dependent siderophore receptor and hypothetical protein were selected as vaccine candidates. From the first protein (TonB-dependent sidero-




FIGURE 2: A number of proteins and their categories.

phore receptor), 10 different epitopes with various lengths were predicted, while from protein 2 (hypothetical protein), only 9 epitopes were predicted. The predicted epitopes are tabulated in Table 1.

3.3. T-Cell Epitope Prediction. Predicted B-cell epitopes were used to predict T-cell epitopes “MHC-I and II epitopes.” The predicted epitopes were ranked on the basis of lower percentile score. T-cell epitopes are tabulated in Table 2.

3.4. Multiepitope Construction and Processing. The predicted T-cell peptide was evaluated for antigenicity, allergenicity, and water solubility. Antigenic, water-soluble, and nonallergenic epitopes were shortlisted for vaccine design. The shortlisted epitopes are tabulated in Table 3.

In the multiepitope vaccine designing phase, the filtered epitopes were connected by “GPGPG” linkers. Additionally, the vaccine was bound to cholera toxin-B subunit adjuvant for boosting immune response. Physiochemical properties of the vaccine construct were analyzed. The server predicted that the vaccine construct comprises 272 amino acids with a molecular weight of 28646.22 and an instability index of 32.67. The VaxiJen 2.0 server predicted that the vaccine construct is probable antigenic with a 0.8925 antigenicity score. The 3D structure was modeled as presented in Figure 3(a), while the schematic representation of the multiepitope vaccine construct is shown in Figure 3(b).

3.5. Validation of Model Stability. The Ramachandran plot analysis shows that favourable areas are occupied by 182 (87.9%) of the residues in the protein model. Additionally, it was found that just 0% of residues were in banned or outline boundaries and that 11.6% (24) of residues were present in allowed regions. The overall number of residues (272), the number of glycine residues (40), the number of proline residues (23), and the number of end residues (2) were all estimated via the PROCHECK service. The overall quality factor of the vaccine construct was 44.4 calculated by the ERRAT tool.

3.6. Disulfide Engineering In Silico Codon Optimization and Loop Refinement. In disulfide engineering, a total number of sixteen pairs of amino acid residues were considered to make disulfide bonds: Ile2-glu125, chi3 value 111.32, and energy value 3.21; Leu14-asp28, chi3 value -65.84, and

TABLE 1: Predicted B-cell epitopes.

Selected proteins	Predicted epitopes
TonB-dependent siderophore receptor	RPTADNRRSIEGQVDRFGKVR
	DVKGRDLRLPRSTYLGASWNRSTYHK
	DHQFNDNWKLSALEYKH
	YVPQRSNVASGTVS
	REKFDNTWHGKKIAGEYNIFRWQGTEIAQPADWNALPEEVRHT
	WQQHQHLSWMSKPD SKYGKGR L
	FKYSGDYLDINGKTL
	QPIDTWKGIDPATGAVREWQRGDRSIYTPVRLQ
	YTSTAATKTITRNGKGVDFSQHTP
	MQSKSSPITVDGNKHYL
Hypothetical protein	Predicted epitopes
	QNAPPPSRALPVDIDRGNERLSEDDVGKNVRLPQVPAVKPAAPTTLPSDAQAAKEDVVYTPEELVNNPEQ
	KLRSGDVSEADRKTL
	IHDNNVNNVAPKGTFRFLSNGRSLSEN RDQEKANGIS
	SGSYFHKRNYNDVTT
	KRLYGRGSNGDNKLHAYSN
	EFSYDKYVRTYDYLDGK
	LSHKGARSASDAYD
	YGKRYSGVDDFNIDREDK
	FSYSKIDSNNRFYSYDAS

energy value 6.81; Ala19-ile38, chi3 value 89.41, and energy value 2.28; Thr27-his34, chi3 -89.18, and energy value 3.29; Thr36-tyr39, chi3 value 116.98, and energy value 3.86; Lys129-asn136, chi3 value -101.93, and energy value 5.9; Ser156-pro161, chi3 value -104.16, and energy value 6.49; Thr157-trp167, chi3 value 98.41, and energy value 2.47; Tyr158-pro161, chi3 value 114.52, and energy value 4.81; Ala172-gly176, chi3 value 69.34, and energy value 4.84; Gly190-pro203, chi3 value 105.85, and energy value 2.6; Leu194-gly198, chi3 value 93.64, and energy value 3.94; Gly198-leu201, chi3 value -61.97, and energy value 5.92; Thr200-pro217, chi3 value 110.96, and energy value 4.06; Gly202-asn207, chi3 value 88.96, and energy value 5.35; Pro203-leu210, chi3 value -92.84, and energy value 4.97. The mutated and original structure of the vaccine construct is mentioned in Figures 4(a) and 4(b).

Furthermore, the optimized sequence had a codon adaptation index (CAI) of 0.973897328694206, indicating an effective expression system in the *E. coli* host with a GC content of 54.04411764705882. The modified codon sequence from the vaccine construct “ATGATCAAAC TGA AATTTGGCGTCTTCTTCACCGTCTGCTGTCTTCTGCTTACGCTCACG GTACCCCGCAGAACATCACCGACCTGTGCGTGAA TACCACAACACC.

AGATCTACACCCTGAACGACAAAATCTTCTCTTA CACCGAATCTCTGGCTGGTAAACGTGAAATGGCTAT CATCACCTTCAAAAACGGTGCTATCTTCCAGGTTGA AGTTCCGGGTTCTCAGCACATCGACTCTCAGAAAAA AGCTATCGAACGTATGAAAGACACCCTGCGTATCGC TTACCTGACCGAAGCTAAAGTTGAAAAACTGTGCGT TTGGAACAACAAAACCCCGCACGCTATCGCTGCTAT CTCTATGGCTAACGAAGCTGCTGCTAAAGAAGCTGC

TGCTAAAGACAACCGTCGTTCTATCGAAGGTCAGGT TGGTCCGGGTCCGGGTGACCTGCGTCTGCCGCGTTC TACCTACCTGGGTCCGGGTCCGGGTGACAACTGCTG CGTCTGCCGCGTCTACCTACCTGGGTCCGGGTCCG GGTGACAACTGGAACTGAACTCTGCTCTGGGTCCG GGTCCGGGTGGATGTCTAAACCGGACTCTAAATAC GGTCCGGGTCCGGGTACCTGGACATCAACGGTAAA ACCCTGGGTCCGGGTCCGGGTAAACGAACGTCTGTCT GAAGACGACGTTGGTCCGGGTCCGGGTCTGTGACCAG GAAAAAGCTAACGGTATCTCTGGTCCGGGTCCGGGT CGTCTGTACGGTCTGTTCTAACGGTGGTCCGGGT CCGGGTCTGTCTCACAAAGGTGCTCGTTCTGCTGGT CCGGGTCCGGGGGTGCTCGTTCTGCTTCTGACGCTT AC” was then inserted in *E. coli* expression vector PET28a (+), as shown in Figure 5. In loops refinement, 10, the model was refined as the data of loops refinement is tabulated in Table S4.

3.7. Molecular Docking Analysis. Interaction of vaccine with host immune cells is vital for inducing immune responses, these interactions were analyzed through molecular docking analysis, and the docking server generated 20 docked complexes as mentioned in supplementary Tables S1-S4. The PDBsum analysis of vaccine 1 revealed 16 hydrogen bonds and 1 salt bridge. Moreover, 42 interface residues were discovered in vaccine 1, covering an interface area of 2,502 (A²), compared to 45 MHC-I interface residues, which covered an area of 2,319 (A²). PDBsum estimated two salt bridges and eight hydrogen bonds for vaccine 2. Additionally, interactions between 26 and 36 MHC-II and vaccine 2 residues occurred over 1,997 and 1,832, respectively. Similar to vaccine 2, PDBsum predicted 14 hydrogen bonds and one salt bridge for vaccine 3. Additionally, 27 and 22 residues

TABLE 2: T-cells epitopes and percentile score.

MHC-I	Percentile score	MHC-II	Percentile score
RSIEGQVDRF	0.09	DNRRSIEGQVDRF	17
DNRRSIEGQV	12	DNRRSIEGQVDRF	17
RPTADNRRSI	0.04	RPTADNRRSIEGQV	44
NRRSIEGQV	9.8	RPTADNRRSIEGQV	44
RSIEGQVDRF	0.09	RSIEGQVDRFGKVR	26
QVDRFGKVR	1.4	RSIEGQVDRFGKVR	26
TYLGASWNR	0.03	STYLGASWNRSTYH	6.1
ASWNRSTYH	0.63	STYLGASWNRSTYH	6.1
DVKGRDLRL	0.08	DVKGRDLRLPRSTYL	9.2
DLRLPRSTYL	0.12	DVKGRDLRLPRSTYL	9.2
KLNSALEYK	0.02	NWKLNSALEYK	0.29
NWKLNSALEY	1.2	NWKLNSALEYK	0.29
HQFNDNWKL	0.06	DHQFNDNWKLNSAL	9.8
DNWKLNSAL	1.5	DHQFNDNWKLNSAL	9.8
NVSASGTVS	10	YVPQRSNVASGTVS	5.2
DWNALPEEV	1.7	QPADWNALPEEV	1.4
QPADWNALP	4.1	QPADWNALPEEV	1.4
IFRWQGTEI	1.4	YNIFRWQGTEIAQP	4.2
WQGTEIAQP	11	YNIFRWQGTEIAQP	4.2
WHGKKIAGE	31	WHGKKIAGE	21
KFDNTWHGK	1.1	REKFDNTWHGKKIA	27
NTWHGKKIA	2.5	REKFDNTWHGKKIA	27
HQHLSWMSK	0.05	HQHLSWMSKPSDK	11
LSWMSKPSDK	0.85	SWMSKPSDKYGKGR	48
WMSKPSDKY	0.08	SWMSKPSDKYGKGR	48
DSKYGKGR	2.6	WQQHQHLSWMSKPS	20
HQHLSWMSK	0.05	WQQHQHLSWMSKPS	20
WQQHQHLSW	0.59	FKYSGDYLDINGKTL	11
LSWMSKPS	21	FKYSGDYLDINGKTL	11
YLDINGKTL	0.14		
FKYSGDYLDI	3.1		

TABLE 3: Selected epitopes for multiepitope vaccine designing.

Selected epitopes	Predicted ic50 value (nm)	Antigenicity	Allergenicity	Toxicity	Water solubility
DNRRSIEGQV	7.242	1.3151			
DLRLPRSTYL	7.558	0.7153			
DNWKLNSAL	6.983	1.1081			
WMSKPSDKY	7.536	0.9954			
YLDINGKTL	6.837	1.4469			
NERLSEDDV	7.174	1.1854	Nonallergic	Nontoxic	Good water solubility
RDQEKANGIS	8.432	1.0961			
RLYGRGSNG	6.764	1.9978			
LSHKGARSA	7.07	1.3193			
GARSASDAY	7.356	0.9841			




FIGURE 3: (a) 3D model of vaccine; (b) schematic representation of model vaccine.




FIGURE 4: Mutant and original structure of model vaccine.




FIGURE 5: Cloned pET28a (+) vector.

TABLE 4: Top-docked complexes with their least binding energy score were selected for simulation.

Top-docked complexes	Global energy	Attractive VdW	Repulsive VdW	ACE	HB
Vaccine-MHC-I	6.89	-4.75	0.92	2.52	16
Vaccine-MHC-II	12.75	-4.94	1.02	1.90	8
Vaccine-TLR-4	-19.51	-12.63	0.91	2.80	14

from vaccine 3 and TLR-4, covering 1,228 and 1,271, respectively, interacted with one another. Further, the docking results were refined, and from refined complexes, top 1 complexes in each case of receptors were considered for the simulation study. The top complexes are tabulated in Table 4 while the docked 3D confirmation of docked complexes is mentioned in Figures 6(a)–6(c).

3.8. Molecular Dynamic Simulation. Molecular dynamic simulation analysis was done for analyzing the movement of the macromolecules docked complexes [46]. MD simulation analysis was carried out for vaccine-MHC-I, MHC- and TLR-R for 100 ns seconds. In MD simulation, root mean square fluctuation (RMSF) and root-mean-square deviation (RMSD) analysis were performed. We observed, in the RMSD, that the vaccine and MHC-II molecule have stable binding affinity as it showed little deviation followed by TLR-4 and vaccine and MHC-I with vaccine as presented in Figure 7(a). Subsequently, RMSF analysis was done to evaluate residue level fluctuation. The RMSF analysis found

lower fluctuations between docked complexes as presented in Figure 7(b). Overall, in the whole period of simulation, no drastic changes were observed in docked complexes.

3.9. Normal Mode Simulation Analysis. In normal mode simulation analysis, the vaccine-immune cell receptor docked complexes are further stimulated for binding stability analysis. Direction of the residues is represented by the arrow in Figures 8–10(a) in which the vaccine construct is shown by red color, while immune cell receptors are represented by blue color. In beta factor mobility analysis, both the vaccine and receptors are found to be mobile proteins that can allow interaction between docked molecules, and the beta factor mobility of vaccine-MHC-I, MHC-II, and TLR-4 is represented in Figures 8–10(b). Next, the experimental B-factor is taken from the corresponding PDB field and the calculated from NMA is obtained by multiplying the NMA mobility by $(8\pi^2)$. Be aware that many PDB files of averaged NMR models contain no B-factors (actually, the B-factor column gives an averaged RMS) as the beta




FIGURE 6: Docked confirmation of vaccine and selected immune cell receptors.




FIGURE 7: Statistical graphs of the simulation trajectories.

factor and NMA of vaccine and MHC-I, MHC-II, and TLR-4 are presented in the following 8, 9 and 10C. The covariance map of vaccine-MHC-I, II, and TLR-4 is shown in Figures 8–10(d), which represents the coupling between pairs of residue, either they are correlated, uncorrelated, or anticorrelated motions which are represented by red, white, and blue, respectively. In the elastic network analysis define pairs of residues connected by springs, each dot in the graph represents one spring between the corresponding pair of atoms. Dots are colored according to their stiffness, the darker grays indicate stiffer springs and vice versa as presented in Figures 8–10(e). The eigenvalue is directly related to the energy required to deform the structure, the lower the eigen-

value, the easier the deformation, the eigenvalue associated to each normal mode shows the stiffness, and the eigenvalue and mode index of vaccine- MHC-I, MHC-II, and TLR-4 are presented in Figures 8–10(f). Furthermore, in variance analysis, the inversely related to the eigenvalue was analyzed in Figures 8–10(g) the colored bars show the individual (red) and cumulative (green) variances in the case of vaccine with MHC-I, MHC-II, and TLR-4, respectively.

3.10. Binding Energy Estimation. In binding energies estimation net binding energies were calculated through Molecular mechanics with generalised Born and surface area solvation (MMGBSA) and Molecular Mechanics Poisson-Boltzmann




FIGURE 8: Statistical analysis of normal mode simulation graphs analysis of vaccine-MHC-I molecule obtained from IMODS server.

Surface Area (MMPBSA), the MMGBSA calculated Delta Total net binding energies for “TLR-4-Vaccine Complex, MHC-I-Vaccine Complex and MHC-II-Vaccine Complex -94,-78 and -76”, respectively. The MM-PBSA analysis calculated -97,-61, and -72 net binding energy for a vaccine with TLR-4, a vaccine with MHC-I-, and vaccine with MHC-II- as mentioned in the following Table 5.

3.11. Chemical Interaction of Vaccine to Immune Cell Receptors. Proper immune responses are not produced if there is no interaction between the host immune cells and

the vaccine. Using a protein-peptide molecular docking technique, it was discovered how chemically the vaccine design interacted with toll-like receptor-4, major histocompatibility complex-I, and major histocompatibility complex-II. Utilizing the UCSF chimera tool, specific amino acid residues base interactions between MCH-I, MCH-II, and TLR-4 were examined. The interactions include both hydrophobic and hydrophilic interactions. Van der Waals, hydrogen bonds, and salt bridge interactions are among the close-proximity interactions that are taking place. One of the several proteins known as toll-like receptors (TLRs) that aid in the initiation of both




FIGURE 9: Statistical analysis of normal mode simulation graphs analysis of vaccine-MHC-II molecule obtained from iMODS server.

acquired and adaptive immune responses is toll-like receptor 4, which is mainly expressed on immune cells. The interactive amino acid with immune cell receptors is tabulated in Table 6.

3.12. In Silico Immune Stimulation. The host immunological simulation carried out by the C-ImmSim server analyzed the host immune response to the vaccine. The server predicted that the designed vaccine construct properly induce an immune response in the form of different antibodies and other cytokines. Antibody response toward vaccine is presented in

Figure 11(a), while other cytokines and interferon are presented in Figure 11(b). Furthermore, toward the vaccine, different interleukins (IL-4 and IL-12) and transforming growth factor-beta (TGF β) are also observed in different levels.

3.13. Population Coverage Analysis of Selected Epitopes. In population coverage analysis, the selected epitopes were tested for population coverage analysis using online immune epitope database; in this analysis, the conserved selected epitopes predicted that the selected epitopes can cover 99.75%




FIGURE 10: Statistical analysis of normal mode simulation graphs analysis of vaccine-TLR-4 molecule obtained from IMODS server.

population of the world, 97.83 population of China, and 97.35% of India followed by Pakistan, and other countries are mentioned in Figure 12; therefore, the selected epitopes were used in the designing of multiantigenic chimeric vaccine construct against the target pathogen.

4. Discussions

Although *C. valvarum* infection may not currently pose a life-threatening threat, medical attention to this opportunistic disease is constantly growing [8]. Several approaches are

TABLE 5: Net binding-free energy calculation.

Energy parameter	TLR-4 and vaccine	MHC-I- and vaccine	MHC-II-and vaccine
<i>MM-GBSA</i>			
VDWAALS	-78.00	-60.00	-65.00
EEL	-45.00	-39.00	-31.00
Delta G gas	-123	-99	-96
Delta G solv	29.00	21.00	20.00
Delta total	-94	-78	-76
<i>MM-PBSA</i>			
VDWAALS	-78.00	-60.00	-65.00
EEL	-45.00	-39.00	-31.00
Delta G gas	-123	-99	-96
Delta G solv	26.00	38.00	24.00
Delta total	-97	-61	-72

TABLE 6: Immune cell receptors and interactive amino acid residues.

Immune cells receptors	Interactive residues
Vaccine-MHCI	Gln180, Lys176, Ala211, Pro210, Glu232, Tyr209, Thr233, Glu177, Thr178, Pro235, Ile7 Tyr26, Pro5, Asn174, Phe30, Thr86, Asp53, Leu87, Ile35, Glu55.
Vaccine-MHC-II	Arg4, Asp17, Val42, Leu14, Phe7, Glu46, Pro81, Glu47, Glu30, Leu38, Val116, His167, His149, Asn118, Val165, Thr129, Cys107, Pro87, Arg146, Leu138.
Vaccine-TLR-4	Leu434, Lys89, Tyr79, Cys390, Glu150, Ile412, Asn86, Gln436, Ile52, Asn433, Ser120, Val411, Glu439, Gln436, Ser441, Glu494, Leu470, Lys477, Asn468, Val442.




FIGURE 11: Production of different antibody titers (a) in response to the vaccine antigen. (b) The concentration of the cytokines and interleukins against the vaccine antigen.

still present to manage bacterial infections by developing preventive measures and vaccinations before the occurrence of infection [47]. *C. valvarum* is unquestionably occurring as a result of the widespread and unchecked use of antibiotics. The pan-genome analysis is an alternative and the reverse of

the pasture vaccinology approach for designing multiepitope constructs against several bacterial pathogens [48]. In addition, the genomic data offered important new information. Several genetic alterations occur during infection due to variances in genome large size and functional genes' developed




FIGURE 12: Population coverage analysis covered by conserved selected antigenic epitopes; the data is generated by the immune epitopes database online web server.

genetic structure. *C. valvarum* strains differ physiologically and genomically [49]. Along with analyzing the *C. valvarum* genome, our goal was to create a multiepitope vaccine to fight this opportunistic infection; as in a previously conducted study, *in silico* vaccine was designed against *Enterococcus mundtii* [29]. To overcome the limitations of this method, other criteria were considered when selecting antigens for vaccine formulation, such as epitope antigenicity, physicochemical stability, nonallergenicity, and nontoxicity. Using epitope mapping and selection, probable antigenic epitopes were selected for vaccine design. As in a previous study, several epitopes were mapped and filtered for multiepitope vaccine construction against *Morganella morganii* to induce a strong immune response against the target pathogen [36]. The conserved and antigenic nature of the discovered T-cell epitopes raises the possibility that they could play a significant role in a designed vaccine. To avoid this, a high-quality and stable three-dimensional structure of the vaccine model was modeled. This study is also aimed at generating both T-cell and B-cell immune activations. Hence, the vaccine comprises both B and T-cell epitopes because T-cell responses not only have a lengthy half-life but can also prevent antigenic drift. The designed vaccine has high thermodynamic viability, stability, hydrophilicity, and expression capacity. No adverse responses are anticipated because the multiepitope vaccine is nonallergenic [39]. Molecular docking and simulation approaches were utilized to evaluate the binding affinity and movement of docked molecules for confirmation of binding stability, similar to a previous study conducted for multiepitope vaccine designing [27], as our findings and the previous study findings support result of each other.

5. Conclusion

Finally, employing a probable vaccine target within *C. valvarum* core proteome, we used computational tools to create an *in silico* vaccine against *C. valvarum*. The discovered proteins were utilized for epitope prediction and to elicit immune responses. The model vaccine has good binding capacity as it is crucial for generating the activation of the immune system. The movement of docked molecules and the interaction of immune cell receptors were further validated through a simulation study. The model vaccine showed the best immunogenicity and was able to induce a proper immune response against the target pathogen. These and other limitations call for further development and investigation in future research efforts. Vaccine development proteins were subjected to highly strict selection and filtering criteria. However, these selection criteria of vaccine targets are required for experimental validation. In conclusion of this study, by applying several immunoinformatics approaches, we observed that our proposed vaccine construct could induce a proper immune response against *C. valvarum* and can reduce the infection caused by the said pathogen. However, our study is based on computational approaches; hence, experimental validation is strongly recommended. The vaccine candidate could speed the vaccine development process during the formulation of a vaccine against the target pathogen.

Data Availability

The data presented in this study are available within the article.

Conflicts of Interest

The author declares no conflict of interest.

Acknowledgments

The authors extend their appreciation to the Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia, for funding this research work through the project number (PSAU/2023/R/1444). This study is supported via funding from the Prince Sattam Bin Abdulaziz University project number (PSAU/2023/R/1444).

Supplementary Materials

Supplementary Table S1: docked solution of vaccine with MHC-I generated by Patch dock server. Supplementary Table S2: docked solution of vaccine with MHC-II generated by Patch dock server. Supplementary Table S3: docked solution of vaccine with a toll-like receptor-4 (TLR-4) generated by Patch dock server. Supplementary Table S4: top 10 refine model generated by refine 2 services in GALAXY webserver. (Supplementary Materials)

References

- [1] R. Cantón and M.-I. Morosini, "Emergence and spread of antibiotic resistance following exposure to antibiotics," *FEMS Microbiology Reviews*, vol. 35, no. 5, pp. 977–991, 2011.
- [2] C. L. Ventola, "The antibiotic resistance crisis: part 1: causes and threats," *Pharmacy and Therapeutics*, vol. 40, no. 4, pp. 277–283, 2015.
- [3] C. Llor and L. Bjerrum, "Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem," *Therapeutic Advances in Drug Safety*, vol. 5, no. 6, pp. 229–241, 2014.
- [4] M. P. da Silveira, K. K. da Silva Fagundes, M. R. Bizuti, É. Starck, R. C. Rossi, and D. T. de Resende e Silva, "Physical exercise as a tool to help the immune system against COVID-19: an integrative review of the current literature," *Clinical and Experimental Medicine*, vol. 21, no. 1, pp. 15–28, 2021.
- [5] R. S. Vasan, S. Pan, M. G. Larson, G. F. Mitchell, and V. Xanthakis, "Arteriosclerosis, atherosclerosis, and cardiovascular health: joint relations to the incidence of cardiovascular disease," *Hypertension*, vol. 78, no. 5, pp. 1232–1240, 2021.
- [6] R. Joye, D. Ceroni, M. Beghetti, Y. Aggoun, and T. Sologashvili, "Fulminant infective endocarditis due to *Kingella kingae* and several complications in a 6-year-old girl: a case report," *Frontiers in Pediatrics*, vol. 9, p. 641, 2021.
- [7] E. Bothelo, F. Gouriet, P. E. Fournier et al., "Endocarditis caused by *Cardiobacterium valvarum*," *Journal of Clinical Microbiology*, vol. 44, no. 2, pp. 657–658, 2006.
- [8] L. Ni, X. Xie, N. Ouyang et al., "A case of *Cardiobacterium valvarum* endocarditis with cerebral hemorrhage after MVR, TVP and vegetation removal operation," *Annals of Clinical Microbiology and Antimicrobials*, vol. 17, no. 1, p. 11, 2018.
- [9] R. Rappuoli, M. Pizza, G. Del Giudice, and E. De Gregorio, "Vaccines, new opportunities for a new society," *Proceedings of the National Academy of Sciences*, vol. 111, no. 34, pp. 12288–12293, 2014.
- [10] M. Kaurav, J. Madan, M. S. Sudheesh, and R. S. Pandey, "Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage," *Artificial Cells, Nanomedicine, and Biotechnology*, vol. 46, Supplement 3, pp. S818–S831, 2018.
- [11] G. Bordenave, "Louis Pasteur (1822-1895)," *Microbes and Infection*, vol. 5, no. 6, pp. 553–560, 2003.
- [12] J. C. Tong and S. Ranganathan, *Computer-aided vaccine design*, Elsevier, 2013.
- [13] K. D. Pruitt, T. Tatusova, and D. R. Maglott, "NCBI reference sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins," *Nucleic Acids Research*, vol. 33, no. Database issue, pp. D501–D504, 2005.
- [14] N. M. Chaudhari, V. K. Gupta, and C. Dutta, "BPGA- an ultra-fast pan-genome analysis pipeline," *Scientific Reports*, vol. 6, no. 1, article 24373, 2016.
- [15] Y. Huang, B. Niu, Y. Gao, L. Fu, and W. Li, "CD-HIT suite: a web server for clustering and comparing biological sequences," *Bioinformatics*, vol. 26, no. 5, pp. 680–682, 2010.
- [16] N. Y. Yu, J. R. Wagner, M. R. Laird et al., "PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes," *Bioinformatics*, vol. 26, no. 13, pp. 1608–1615, 2010.
- [17] L. Chen, J. Yang, J. Yu et al., "VFDB: a reference database for bacterial virulence factors," *Nucleic Acids Research*, vol. 33, Supplement_1, pp. D325–D328, 2005.
- [18] Y. Chen, P. Yu, J. Luo, and Y. Jiang, "Secreted protein prediction system combining CJ-SPHMM, TMHMM, and PSORT," *Mammalian Genome*, vol. 14, no. 12, pp. 859–865, 2003.
- [19] I. A. Doytchinova and D. R. Flower, "VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines," *BMC Bioinformatics*, vol. 8, no. 1, pp. 1–7, 2007.
- [20] I. Dimitrov, I. Bangov, D. R. Flower, and I. Doytchinova, "AllerTOP v.2—a server for in silico prediction of allergens," *Journal of Molecular Modeling*, vol. 20, no. 6, p. 2278, 2014.
- [21] ProtParam, E, *ExPASy-ProtParam Tool*, 2017.
- [22] N. Blast, *Basic Local Alignment Search Tool*, Natl. Libr. Med. Natl. Cent. Biotechnol. Inf, 2015.
- [23] R. Vita, J. A. Overton, J. A. Greenbaum et al., "The immune epitope database (IEDB) 3.0," *Nucleic Acids Research*, vol. 43, no. D1, pp. D405–D412, 2015.
- [24] M. C. Jespersen, B. Peters, M. Nielsen, and P. Marcatili, "BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes," in *Nucleic Acids Research*, vol. 45, no. W1, pp. W24–W29, 2017.
- [25] H. Dorosti, M. Eslami, M. Negahdaripour et al., "Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine," *Journal of Biomolecular Structure & Dynamics*, vol. 37, no. 13, pp. 3524–3535, 2019.
- [26] T. H. Albekairi, A. Alshammari, M. Alharbi et al., "Designing of a novel multi-antigenic epitope-based vaccine against *E. hormaechei*: an intergraded reverse vaccinology and immunoinformatics approach," *Vaccines*, vol. 10, no. 5, p. 665, 2022.
- [27] M. Ud-din, A. Albutti, A. Ullah et al., "Vaccinomics to design a multi-epitopes vaccine for *Acinetobacter baumannii*," *International Journal of Environmental Research and Public Health*, vol. 19, no. 9, p. 5568, 2022.
- [28] S. Ismail, S. Ahmad, and S. S. Azam, "Vaccinomics to design a novel single chimeric subunit vaccine for broad- spectrum immunological applications targeting nosocomial Enterobacteriaceae

- pathogens," *European Journal of Pharmaceutical Sciences*, vol. 146, p. 105258, 2020.
- [29] M. Alharbi, A. Alshammari, A. F. Alasmari et al., "Designing of a recombinant multi-epitopes based vaccine against *Enterococcus mundtii* using bioinformatics and immunoinformatics approaches," *International Journal of Environmental Research and Public Health*, vol. 19, no. 6, p. 3729, 2022.
- [30] E. Gasteiger, C. Hoogland, A. Gattiker et al., "Protein identification and analysis tools on the ExPASy server," in *The Proteomics Protocols Handbook*, pp. 571–607, Humana Press, 2005.
- [31] S. Ismail, F. Shahid, A. Khan et al., "Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance," *Computers in Biology and Medicine*, vol. 136, p. 104705, 2021.
- [32] J. Cheng, A. Z. Randall, M. J. Sweredoski, and P. Baldi, "SCRATCH: a protein structure and structural feature prediction server," *Nucleic Acids Research*, vol. 33, no. Web Server issue, pp. W72–W76, 2005.
- [33] R. Ojha, R. K. Pandey, and V. K. Prajapati, "Vaccinomics strategy to concoct a promising subunit vaccine for visceral leishmaniasis targeting sandfly and leishmania antigens," *International Journal of Biological Macromolecules*, vol. 156, pp. 548–557, 2020.
- [34] L. Heo, H. Park, and C. Seok, "GalaxyRefine: protein structure refinement driven by side-chain repacking," *Nucleic Acids Research*, vol. 41, no. W1, pp. W384–W388, 2013.
- [35] P. Craig, A. Cannon, R. Kukla, and J. Kennedy, "MaTSE: the gene expression time-series explorer," *BMC Bioinformatics*, vol. 14, no. S19, p. S1, 2013.
- [36] A. Ullah, S. Ahmad, S. Ismail et al., "Towards a novel multi-epitopes chimeric vaccine for simulating strong immune responses and protection against *Morganella morganii*," *International Journal of Environmental Research and Public Health*, vol. 18, no. 20, p. 10961, 2021.
- [37] D. Schneidman-Duhovny, Y. Inbar, R. Nussinov, and H. J. Wolfson, "PatchDock and SymmDock: servers for rigid and symmetric docking," *Nucleic Acids Research*, vol. 33, no. Web Server, pp. W363–W367, 2005.
- [38] N. Andrusier, R. Nussinov, and H. J. Wolfson, "FireDock: fast interaction refinement in molecular docking," *Proteins: Structure, Function, and Bioinformatics*, vol. 69, no. 1, pp. 139–159, 2007.
- [39] S. Gul, S. Ahmad, A. Ullah et al., "Designing a recombinant vaccine against *Providencia rettgeri* using immunoinformatics approach," *Vaccine*, vol. 10, no. 2, p. 189, 2022.
- [40] D. A. Case, *Others, AMBER16 Package*, Univ. California, San Fr, 2016.
- [41] D. A. Case, "The FF14SB force field," *Amber*, vol. 14, pp. 29–31, 2014.
- [42] A. Alshammari, M. Alharbi, A. Alghamdi et al., "Computer-aided multi-epitope vaccine design against *Enterobacter xiangfangensis*," *International Journal of Environmental Research and Public Health*, vol. 19, no. 13, p. 7723, 2022.
- [43] B. R. Miller, T. D. McGee, J. M. Swails, N. Homeyer, H. Gohlke, and A. E. Roitberg, "MMPBSA.py: an efficient program for end-state free energy calculations," *Journal of Chemical Theory and Computation*, vol. 8, no. 9, pp. 3314–3321, 2012.
- [44] T. Rida, S. Ahmad, A. Ullah et al., "Pan-genome analysis of oral bacterial pathogens to predict a potential novel multi-epitopes vaccine candidate," *International Journal of Environmental Research and Public Health*, vol. 19, no. 14, p. 8408, 2022.
- [45] F. Castiglione and M. Bernaschi, "C-immsim: playing with the immune response," in *Proceedings of the Sixteenth International Symposium on Mathematical Theory of Networks and Systems (MTNS2004)*, Catholic University of Leuven (K.U.Leuven-Belgium), 2004.
- [46] K. S. Allemailem, "A comprehensive computer aided vaccine design approach to propose a multi-epitopes subunit vaccine against *Genus Klebsiella* using pan-genomics, reverse vaccinology, and biophysical techniques," *Vaccine*, vol. 9, no. 10, p. 1087, 2021.
- [47] H. L. Robinson and R. R. Amara, "T cell vaccines for microbial infections," *Nature Medicine*, vol. 11, no. S4, pp. S25–S32, 2005.
- [48] A. Hassan, A. Naz, A. Obaid et al., "Pangenome and immunoproteomics analysis of *Acinetobacter baumannii* strains revealed the core peptide vaccine targets," *BMC Genomics*, vol. 17, no. 1, p. 732, 2016.
- [49] M. O'Bleness, V. B. Searles, A. Varki, P. Gagneux, and J. M. Sikela, "Evolution of genetic and genomic features unique to the human lineage," *Nature Reviews Genetics*, vol. 13, no. 12, pp. 853–866, 2012.